Summary
The study of the plasminogen-plasmin system has, in the past, contributed much to the understanding of fibrinolysis and thrombolysis. Attention is now focused on the role of the components of this system in many biologic functions. Findings of uPA, its receptor and its inhibitor in many tumor tissues and tumor cell lines, strongly implicate their involvement in tumor invasion, tumor cell proliferation and metastasis. The characteristics of the plasminogen activators, the uPA receptor and the plasminogen activator inhibitors as well as their expression and regulation in tumors and tumor cell lines are reviewed.
Similar content being viewed by others
References
BachmannF: Fibrinolysis. In: VerstraeteM, VermylenJ, LijnenR, ArnoutJ (eds) Thrombosis and Haemostasis. Belgium University Press, Leuven, 1987, pp 227–266
BlasiF: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73–84, 1988
MilesLA, PlowEF: Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 2: 61–71, 1988
DanoK, AndreasenPA, Grondahl-HansenJ, KristensenP, NielsenLS, SkriverL: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 140–239, 1985.
LaihoM, Keski-OjaJ: Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 44: 2535–2553, 1989
MarkusG: The relevance of plasminogen activators to neoplastic growth. Enzyme 40: 158–172, 1988
TestaJE, QuigleyJP: The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Reviews 9: 355–367, 1990
KwaanHC, KeerHN: Fibrinolysis and cancer. Sem Thromb Hemost 16: 230–235, 1990
RobbinsKC: The plasminogen plasmin system. In: ColmanRH, HirshJ, MarderVJ (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott, Philadelphia, PA (ed 2), 1987, pp 340–357
HenkinJ, MarcotleP, YangM: The plasminogen-plasmin system. Prog Cardiovasc Dis 34: 135–164, 1991
RobbinsKC, SummariaL, HsiehB, ShahRJ: The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 242: 2332–2342, 1967
RobbinsKC, BernabeP, ArzadonL, SummariaL: NH2-terminal sequences of animal plasminogen and plasmin S-carboxymethyl heavy (A) and light (B) chain derivatives: a re-evaluation of the mechanisms of activation of plasminogen. J Biol Chem 248: 7242–7246, 1973
AstrupT: Fibrinolysis: an overview. In: DavisonJF, RowanRM, SamamaMM, DesnoyersPC (eds) Progress in Chemical Fibrinolysis and Thrombolysis. Raven Press, New York, Vol 3, 1978, pp 1–89
Sottrup-JensenL, ClaeysH, ZajdelM, PetersenTE, MagnussonS: The primary structure of human plasminogen: Isolation of two lysine-binding fragments and one ‘mini-plasminogen’ (MW 38,000) by elastase-catalyzed-specific limited proteolysis. Prog Chem Fibrinolysis Thrombolysis 3: 191–209, 1978
PetersenTE, MartzenMR, IchinoseA, DavieEW: Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 265: 6101–6111, 1990
ClaeysH, MollaA, VerstraeteM: Conversion of NH2-terminal glutamic acid to NH2-terminal lysine human plasminogen by plasmin. Thromb Res 3: 515–523, 1973
MilesL, DahlbergC, PlowE: The cell binding domains of plasminogen and their function in plasma. J Biol Chem 263: 11928–11934, 1988
SugiyamaN, IwamotoM, AbikoA: Effects of kringles derived from human plasminogen on fibrinolysisin vitro. Thromb Res 47: 459–468, 1987
WimanB, LijnenHR, CollenD: On the specific interaction between the lysine-binding sites in plasminogen and complementary sites in a2-antiplasmin and in fibrinogen. Biochim Biophys Acta 579: 142–154, 1979
ValiZ, PatthyL: The fibrin-binding site of human plasminogen. Arginines 32 and 34 are essential for fibrin affinity of the kringle 1 domain. J Biol Chem 259: 13690–13694, 1984
SugiyamaN, SasakiT, IwamotoM, AbikoY: Binding site of a2-plasmin inhibitor to plasminogen. Biochim Biophys Acta 952: 1–7, 1988
StevensR, PollanenJ, TapiovaaraH, LeungKC, SimPS, SalonenEM, RonneE, BehrendtN, DanoK, VaheriA: Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 108: 1987–1995, 1989
LongstaffC, GaffneyPJ: Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry 30: 979–986, 1991
ThorsenS: Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation influence of w-aminocarboxylic acids. Biochim Biophys Acta 393: 55–65, 1975
MarkusG, DePasqualeJL, WisslerFC: Quantitative determination of the binding of E-aminocaproic acid to native plasminogen. J Biol Chem 253: 727–732, 1978
MurphyJC, BuetowKH, DonovanM, HornungS, MotulskyAG, DistecheC, DyerK, SwisshelmK, GiblettE: Linkage disequilibrium of plasminogen polymorphisms and assignment of the gene to human chromosome 6q26–6q27. Am J Hum Gene 40: 338–350, 1987
RaumD, MarcusA, AlperCA: Genetic polymorphism of human plasminogen. Am J Hum Genet 32: 681–689, 1980
RobbinsKC: Dysplasminogenemias. Prog Cardiovasc Dis 4: 295–308, 1992
HeCS, WilhelmSM, PentlandAP, MarmerBL, GrantGA, EisenAZ, GoldbergGI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86: 2632–2636, 1989
MullinDE, RorlichST: The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695: 177–214, 1983
TryggvasonnK, HoyhtyaM, SaloT: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191–217, 1987
O'GradyRL, UpfoldLI, StephensRW: Rat mammary carcinoma cells secrete active collagenase and active latent enzymes in the stroma via plasminogen activator. Int J Cancer 28: 509–515, 1981
SaloT, LiottaLA, Keski-OjaJ, TurpeenieMI, HujanenT, TryggvasonnK: Secretion of basement membrane collagens degrading enzyme and plasminogen activator by transformed cells — role in metastasis. Int J Cancer 30: 669–673, 1982
BlasiF, RiccioA, SebastiG: Human plasminogen activators. Genes and protein structures. In: BlasiF (ed) Human Genes and Diseases. John Wiley & Sons, New York, 1986, pp 377–392
NyT, ElghF, LundB: The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 81: 5355–5359, 1984
VerstraeteM, SuCAPF, TanswellP, FeuererW, CollenD: Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemost 56: 1–5, 1986
KwaanHC, LoR, McFadzeanAJS: On the production of plasma fibrinolytic activity within veins. Clin Sci 16: 241–253, 1957
KwaanHC, LoR, McFadzeanAJS: The production of plasma fibrinolytic activityin vivo by serotonin (5-hydroxytryptamine) creatine sulphate. Clin Sci 16: 255–259, 1957
KwaanHC, McFadzeanAJS, CookJ: On plasma fibrinolytic activity induced by ischemia. Clin Sci 15: 245–258, 1956
KwaanHC, LoR, McFadzeanAJS: On the lysis of thrombi experimentally produced within veins. Br J Haematol 4: 51–62, 1958
TateKM, HigginsDL, HolmesWE, WinklerME, HeynekerHL, VeharGA: Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 26: 338–343, 1987
BachmannF, KruithofEKO: Tissue plasminogen activator: Chemical and physiological aspects. Sem Thromb Hemost 10: 6–17, 1984
RijkenDC, WijngaardsG, CollenD: Tissue-type plasminogen activator from human tissue and cell cultures and its occurrence in plasma. In: CollenD, LijnenHR, VerstraeteM (eds) Thrombolysis, Biological and Therapeutic Properties of New Thrombolytic Agents. Churchill Livingstone, Edinburgh, 1985, pp 15–30
RanbyM, WallenP: Enzymatic properties of tissue-type plasminogen activator. In: CollenD, LijnenHR, VerstraeteM (eds) Thrombolysis, Biological and Therapeutic Properties of New Thrombolytic Agents. Churchill Livingston, Edinburgh, 1985, pp 31–48
NorrmanB, WallenP, RanbyM: Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. Eur J Biochem 149: 193–200, 1985
SobelGW, MohlerSR, JonesNW, MillerKR, PelusoR: Urokinase: An activator of plasma profibrinolysin extracted from urine. Am J Physiol 171: 768–769, 1952
WhiteWF, BarlowGH, MozenMM: The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5: 2160–2169, 1966
BernikMB, KwaanHC: Origin of fibrinolytic activity in cultures of the human kidney. J Lab Clin Med 70: 650–661, 1967
BernikMB, KwaanHC: Plasminogen activator activity in cultures form human tissues. An immunological and histochemical study. J Clin Invest 48: 1740–1753, 1969
BernikM, KwaanHC: Inhibitors of fibrinolysis in human tissues in culture. Am J Physiol 221: 916–921, 1971
GunzlerWA, SteffensGJ, OttingF, KimSM, FrankusE, FloheL: The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z Physiol Chem 363: 1155–1165, 1982
HusainSS, GurewichV, LipinskiB: Purification and partial form characterization of a single-chain high-molecular-weight of urokinase from urine. Arch Biochem Biophys 220: 31–38, 1983
BernikMB, OhlerEP: Plasminogen activator and proactivator (urokinase precursor) in lung cultures. J Am Med Wom Assoc 31: 465–472, 1976
IchinoseA, FujikawaK, SuyamaT: The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261: 3486–3489, 1986 1983
RajputA, DegenSF, ReichE, WallerEK, AxelrodJ, EddyRL, ShowsTB: Chromosomal locations of human tissue plasminogen activator and urokinase genes. Science 230: 672–674, 1985
DeMunkGAW, RiijkenDC: Fibrinolytic properties of single chain urokinase-type plasminogen activator (prourokinase). Fibrinolysis 4: 1–9, 1990
PatthyL, TrexlerM, ValiZ, BanyaiL, VaradiA: Kringles: Modules specialized for protein binding. Homology of the gelatinbinding region of fibronectin with the kringle structures of proteins. FEBS Lett 171: 131–136, 1984
LijnenHR, ZamarronC, BlaberM, WinklerME, CollenD: Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 261: 1253–1258, 1986
MarcottePA, DudlakD, LeskiML, HenkinRJ: Characterization of a metalloproteinase which cleaves with high site specificity the Glu(143)-Leu(144) bond or urokinase. Fibrinolysis 6: 57–62, 1992
RabbaniSA, DesjardinsJ, BellAW, BanvilleE, GolzmanD: An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is motogenic for osteoblast-like cells. Biochem Biophys Res Commun 173: 1058–1064, 1990
FaribairnS, GilbertR, OjakianG, SchwimmerR, QuigleyJP: The extracellular matrix of normal chick embryo fibroblasts: Its effect on transformed chick fibroblasts and its proteolytic degradation by the transformation. J Cell Biol 101: 1790–1798, 1985
AokiN, HarpelPC: Inhibitors of the fibrinolytic enzyme system. Sem Thromb Hemost 10: 24–41, 1984
CollenD: Report of meeting of the subcommittee on fibrinolysis. San Diego. Thromb Hemostasis 54: 803, 1985
NyT, SawdeyM, LawrenceD, MillanJL, KoskutoffDJ: Cloning and sequence of a cDNA coding for the human B-migrating endothelial-cell-type plasminogen activator. Proc Natl Acad Sci USA 83: 6776–6780, 1986
PannekoekH, VeermanH, LambersH, DiergaarseP, VerweijCL, VanZonneveldAJ, VanMourikJA: Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. EMBO J 5: 2539–2544, 1986
GinsburgD, ZehebR, YangAY, RaffertyUM, AndreasenPA, NielsenL, DanoK, LeboRV, GelehrterTC: cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 78: 1673–1680, 1986
WunTC, KretzmerKK: cDNA cloning and expression of E coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell. FEBS Lett 210: 11–16, 1987
KruithofEKO, Tran-ThangC, RansijnA, BachmannF: Demonstration of a fast-acting inhibitor of plaminogen activators in human plasma. Blood 64: 907–913, 1984
Juhan-VagueI, MoermanB, DeCockF, AillaudMF, CollenD: Plasma levels of a specific inhibitor of tissuetype plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 33: 523–530, 1984
SprengersED, PrincenHMG, KooistraT, VanHinsberghVWM: Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 105: 751–758, 1985
KwaanHC, SuwanwelaN: Inhibitors of fibrinolysis in platelets in polycythaemia vera and thrombocytosis. Br J Haematol 21: 313–322, 1971
SprengersED, AkkermanJW, JansenBG: Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitors in human blood. Thromb Haemostasis 55: 325–329, 1986
KruithofEKO, Tran-ThangC, BachmannF: Studies on the release of a plasminogen activator in inhibitor by human platelets. Thromb Haemostasis 55: 201–205, 1986
ColucciM, ParamoJA, CollenD: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75: 818–824, 1985
EmeisJJ, KooistraT: Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue type plasminogen activatorin vivo and in cultured endothelial cells. J Exp Med 163: 1260–1266, 1986
ParamoJA, ColucciM, CollenD, van derWerfF: Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291: 573–574, 1985
D'AngeloA, KluftC, VerheijenJH, RijkenDC, MozziE, MannucciPM: Fibrinolytic shut-down after surgery: Impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 15: 308–312, 1985
LevinEG, SantellL: Association of a plasminogen activator inhibitor with the growth substrata and membrane of human endothelial cells. J Cell Biol 105: 2543–2549, 1987
KawanoT, MorimotoK, UemuraY: Urokinase inhibitor in human placenta. Nature London 217: 253–254, 1968
WohlwendA, BelinD, VassalliJD: Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 165: 320–339, 1987
AstedtB, LacanderI, NyT: The placental type plasminogen activator inhibitor PAI-2. Fibrinolysis 1: 203–208, 1987
SchleuningWD, MedcalfRL, HessionC, RothenbuhlerR, ShawA, KruithofEKO: Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 7: 4564–4567, 1987
YeRD, WunTW, SadlerJE: cDNA cloning and expression in Escherichia coli of plasminogen activator inhibitor from human placenta. J Biol Chem 262: 3718–3725, 1987
WebbAC, CollinsKL, SnyderSE, AlexanderSJ, RosenwasserLJ, EddyRL, ShowsTB, AuronPE: Human monocyte arg-serpin cDNA. Sequence, chromosomal assignment and homology to plasminogen activator inhibitor. J Exp Med 166: 77–94, 1987
GentonC, KruithofEKO, SchleuningWD: Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase type plasminogen activator in human U-937 lymphoma cell. J Cell Biol 104: 705–712, 1987
BelinD, WohlwendA, SchleuningWD, KruithofEK, VassalliJD: Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activator inhibitor 2. EMBO J 8: 3287–3294, 1989
KruithofEKO, VassalliJD, SchleuningWD, MattalianoRJ, BachmannF: Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 261: 11207–11213, 1986
ChristensenU, HolmbergL, BlahaB, AstedtB: Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue. Thromb Heamostasis 48: 24–26, 1982
LecanderI, AstedtB: Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haemat 62: 221–228, 1986
HeebMJ, EspanaF, GeigerM, CollenD, StumpDC, GriffinJH: Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor 3. J Biol Chem 262: 15813–15816, 1987
BakerJB, LowDA, SimmerRL, CunninghamDD: Protease nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21: 37–45, 1980
EatonDL, BakerJB: Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmin serine protease inhibitor. J Cell Physiol 117: 175–182, 1983
KoideT, FosterD, YoshitakeS, DavieEW: Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its DNA. Biochemistry 25: 2220–2225, 1986
SilversteinRL, LeungLLK, NachmanRI: Thrombospondin: A versitle multifunctional glycoprotein. Arteriosclerosis 6: 245–253, 1986
NielsenLS, KellermanGM, BehrendtN, PiconeR, DanoK, BlasiF: A 55,000–60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 263: 2358–2363, 1988
RoldanAL, CubellisMW, MasucciMT, BehrendtN, LundLR, DanoK, AppellaE, BlasiF: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467–474, 1990
PlougM, RonneE, BehrendtN, JensenAL, BlasiF, DanoK: Cellular receptor for urokinase plasminogen activator: Carboxylterminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 266: 1926–1933, 1991
PlougM, BehrendtN, LoberD, DanoK: Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Sem Throm Hemost 17: 183–193, 1991
PlougM, PlesnerT, RonneE, EllisV, Hoyer-HansenG, HansenNE, KanoK: The receptor for urokinase-type plasminogen activator is deficient of peripheral blood leukocytes in patients with paroxysal nocturnal hemoglobinuria. Blood 79: 1447–1455, 1992
VassalliJD, BaccinoD, BelinD: A cellular binding site for the Mr55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92, 1985
StoppelliMP, CortiA, SoffientiniA, CassaniG, BlasiF, AssoianRK: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activators to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82: 4939–4943, 1985
AppellaE, RobinsonEA, UllrichSJ, StoppelliMP, CortiA, CassaniG, BlasiF: The receptor-binding sequence of urokinase. A biological function of the growth factor module of protease. J Biol Chem 262: 4437–4440, 1987
BlasiF: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73–84, 1988
PiconeR, KajtaniakEL, NielsenLS, BehrendtN, MastronocolaMR, CubellisMV, StopelliMP, PedersenS, DanoK, BlasiF: Regulation of urokinase receptors in monocyte-like U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 108: 693–702, 1989
EllisV, ScullyMF, KakkarVV: Plasminogen activator initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264: 2185–2188, 1989
EllisV, DanoK: Plasminogen activation by receptor-bound urokinase. Sem Thromb Hemost 17: 194–200, 1991
Ellis V, Behrendt H, Dano K: Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem 12752–12758, 1991
BoydD, FlorentG, KimP, BrattainM: Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112–3116, 1988
EllisV, WunTC, BehrendtH, RonneE, DanoK: Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 265: 9904–9908, 1990
PollanenJ, SakselaO, SalonenEM, AndreasenP, NielsenL, DanoK, VaheriA: Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104: 1085–1096, 1987
TakahashiK, KwaanHC, KohE, TanabeM: Enzymatic properties of the phosphorylated urokinase-type plasminogen activator isolated from a human carcinomatous cell line. Biochem Biophys Res Commun 182: 1473–1481, 1992
TakahashiK, KwaanHC, IkeoK, KohE: Phosphorylation of a surface receptor bound urokinase type plasminogen activator in a human metastatic carcinomatous cell line. Biochem Biophys Res Commun 182: 1466–1472, 1992
Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1079–1085, 1990
HollasW, BoydD: Regulation of the urokinase receptor by its plasminogen activator. Thromb Haemostasis 66: 678–683, 1991
BussoN, BelinD, Failly-CrepinC, VassalliJD: Plasminogen activators and their inhibitors in human mammary cell line (HBL-100): Modulation by glucocorticoids. J Biol Chem 261: 9309–9315, 1986
GelehrterTD, Sznycer-LaszukR, ZehebR: Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity; paradoxical induction of both tPA antigen and plasminogen activator inhibitor. Mol Endocrin 1: 97–101, 1987
OhlssonM, PengXR, LiuYX, JaiXC, HsuehAJW, NyT: Hormone regulation of tissue-type plasminogen activator gene expression and plasminogen activator mediated proteolysis. Sem Thromb Hemost 17: 286–290, 1991
StricklandS, BeersWH: Studies on the role of plasminogen activator in ovulation. J Biol Chem 18: 5694–5702, 1976
HoviT, SakselaO, VaheriA: Increased secretion of plasminogen activator by human macrophages after exposure to leukocyte interferon. FEBS Lett 129: 233–236, 1981
CollartMA, BelinD, VassalliJD, deRosodoS, VassalliP: Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin-1 and urokinase genes which are controlled by short-lived repressors. J Exp Med 164: 2113–2118, 1986
EmeisJJ, KooistraT: Interleukin 1 and lipopolysaccharide induce and inhibitor of tissue-type plasminogen activatorin vivo and in cultured endothelial cells. J Exp Med 163: 1260–1266, 1966
SchleefRR, BeavlacquaMP, SawdwyM: Cytokine activation of vascular endothelium: Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263: 5797–5803, 1988
GalwayB, OikawaM, NyT, HsuehAV: Epidermal growth factor stimulates tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells: Mediation by pathways independent of protein kinase A and C. Endocrinol 125: 126–135, 1989
KesslerTL, MarkusG: Epidermal growth factor and 12-Tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells. Sem Thromb Hemost 17: 217–224, 1991
Keski-OjaJ, KoliK, LohiJ, LaihoM: Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Sem Thromb Hemost 17: 231–239, 1991
VanHinsbergVWM, van denBergEA, FiersW, DooijewaardG: Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75: 1991–1998, 1990
LevinEG, LoskutoffDJ: Regulation of plasminogen activator production by cultured endothelial cells. Ann NY Acad Sci 401: 184–194, 1982
GospodarwoiczD, FerraraN, SchweigererL, NeufeldG: Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8: 95–114, 1987
UnsickerK, Reichert-PreibschH, SchmidtR, PettmanB, LabourdetteG, SensenbrennerM: Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. Proc Natl Acad Sci USA 84: 5459–5463, 1987
MoscatelliD, PrestaM, RifkinDB: Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration. Proc Natl Acad Sci USA 83: 2091–2095, 1986
PrestaM, MoscatelliD, Joseph-SilversteinJ, RifkinDB: Purification from a hepatoma cell line a basic fibroblast growth factor-like molecule which stimulates capillary endothelial cell plasminogen activator production, DNA synthesis and migration. Mol Cell Biol 6: 4060–4066, 1986
SakselaO, MoscatelliD, RifkinDB: The opposing effects of basic fibroblast growth factor and transforming growth factor B on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105: 957–963, 1987
BjorkerudS: Impaired fibrinolysis-induced capacity for postinjury phenotype of cultivated human arterial and human atherosclerotic intimal smooth muscle cells. Circulation Res 62: 1011–1018, 1988
RossG, GlomsetJ, KariyaB, HarkerL: A platelet-derived serum factor that stimulates the proliferation of arterial smooth muscle cellsin vitro. Proc Natl Acad Sci USA 71: 1207–1210, 1974
Bowen-PopeDF, RossR, SeifertRA: Locally acting growth factors for vascular smooth muscle cells: endogenous synthesis and release from platelets. Circulation 72: 735–740, 1985
LinHS, GordonS: Secretion of plasminogen activator by bone marrow-derived mononuclear phagocytes and its enhancement by colony-stimulating factors. J Exp Med 150: 231–245, 1979
SakselaO, RifkinDB: Cell-associated plasminogen activation: Regulation and physiological functions. Ann Rev Cell Biol 4: 93–126, 1988
Keski-OjaJ, BlasiF, LeofEB, MosesHL: Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol 106: 451–459, 1988
SakselaO: Plasminogen activation of regulation of pericellular proteolysis. Biochim Biophys Acta 823: 35–65, 1985
LyonsRM, Keski-OjaJ, MosesHL: Proteolytic activation of latent transforming growth factor B from fibroblast conditioned medium. J Cell Biol 106: 1659–1665, 1988
SatoY, TsuboiR, LyonsR, MosesHL, RifkinDB: Characterization of the activation of latent TGFB by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system. J Cell Biol 111: 757–763, 1990
TestaJE, MedcalfRL, CajorJF, SchleuningWD, SordatB: Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells. Int J Cancer 43: 816–822, 1989
BellSM, BrackenburyRW, LeslieND, DegenJL: Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters. J Biol Chem 265: 1333–1338, 1990
TrousseauA: Phlegmasia alba dolens. In: Clinique Medicale de Hotel Dieu de Paris. Balliere, Paris, 2nd Ed, Vol 3, 1865, p 654
EsparazB, KiesMS, KwaanHC: Thromboembolism and cancer. In: KwaanHC, SamamaMM (eds) Clinical Thrombosis. CRC Press, Inc., Boca Raton, FL 1989, pp 317–334
JamesGI, MathesonNM: Thrombophlebitis in cancer. Practitioner 134: 683–684, 1935
ThompsonAP: Thrombosis of the peripheral veins in visceral cancer. Clin J 67: 137–143, 1938
SproulEE: Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body of tail of the pancreas with multiple venous thromboses. Am J Cancer 34: 566–582, 1938
KenneyWE: The association of carcinoma in the body and tail of the pancreas with multiple venous thrombi. Surgery 14: 600–609, 1943
InnerfeldI, AnristA, BenjaminJW: Plasma antithrombin patterns in disturbances of the pancreas. Gastroenterol 19: 843–851, 1951
CoonW, CollerF: Some epidemiologic considerations of thromboembolism. Surg Gynecol Obstet 109: 485–487, 1959
PhillipsLL, SkrodelisV, FureyCA: The fibrinolytic enzyme system in prostatic cancer. Cancer 12: 721–732, 1959
HalpertB, MakkL, JordanG: A retrospective study of 120 patients with carcinoma of the pancreas. Surg Gynecol Obstet 121: 91–103, 1965
MillerSP, Sanchez-AvalosJ, StefanskiT: Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 20: 1452–1465, 1967
FriemanDG: Venous thromboembolic disease in malignant states. In: Thrombosis. Natl Acad, Washington, DC, 1969, p 5
DavisRB, TheologidesA, KennedyBJ: Comparative studies of blood coagulation and platelet aggregation in patients with cancer and non-malignant diseases. Ann Intern Med 71: 67–80, 1969
BrugarolasA, MikIB, EliasEG, MittelmanA: Correlation of hyperfibrinogenemia with major thromboembolism in patients with cancer. Surg Gynecol Obstet 136: 75–77, 1981
SlichterSJ, HarkerLA: Hemostasis in malignancy. Ann NY Acad Sci 230: 252–261, 1974
PineoGF, BrainMC, GallusAS, HirshJ, HattonMW, RegoecziE: Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 23: 262–270, 1974
WajimaT: Thrombophlebitis in cancer patients. Ann NY Acad Sci 370: 138–144, 1981
EdwardsEA: Migrating thrombophlebitis associated with carcinoma. N Eng J Med 1031: 204–212, 1959
SchmaierAH, DayJH: A classification of disorders of hemostasis and thrombosis in patients with malignancy. Prog Clin Biol Res 89: 1–20, 1982
RennieJW, OgstonD: Fibrinolytic activity in malignant disease. J Clin Pathol 28: 872–874, 1975
OgstonD, DawsonAA: The fibrinolytic system in malignant lymhomas. Acta Haematologica 49: 89–95, 1973
GoreM, MillerKE, SoongSJ, Clarke-PearsonDL, PizzoSV: Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. Am J Obstet Gynecol 149: 830–834, 1985
RennieJA, OgstpmD: Fibrinolytic activity in malignant disease. J Clin Path 28: 872–874, 1975
DeJongE, KnotEAR, PikerD, IburgAHC, RijkenCD, VeenhofKHN, DooijewaardG, TenCateJW: Increased plasminogen activator inhibition levels in malignancy. Thromb Haemost 57: 140–143, 1987
KirchheimerJC, HuberK, WagnerO, BinderBR: Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol 66: 85–89, 1987
ParamoJA, CampbellW, CuestaB, GomezC, ArandaA, RochaE: Fibrinolytic response in malignancy. Fibrinolysis 1: 195–199, 1987
ParamoRE, FernandezFJ, CuestaB, HernandezM, PalomaMJ, RifonJ: Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 54: 699–707, 1989
KwaanHC, LoR, McFadzeanAJS: Antifibrinolytic activity in primary carcinoma of the liver. Clin Sci 18: 251–261, 1959
GralnickHR, GivelberH, AbramsE: Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. N Eng J Med 299: 221–232, 1978
TsudaH, OkaK, NoutsukaY, SueishiK: Tissue-type plasminogen activator in patients with intracranial meningiomas. Thromb Haemost 60: 508–513, 1988
TallmanMS, KwaanHC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79: 543–553, 1992
RuoslahtiE: Fibronectin and its receptors. Ann Rev Biochem 57: 375–413, 1988
HynesRO: Integrins: A family of cell surface receptors. Cell 48: L549–554, 1987
RuoslahtiE, PierschbacherMD: New perspectives in cell adhesion, RGC and integrins. Science 238: 491–497, 1987
MurphyG, DochertyAJP: Molecular studies on the connective tissue metalloproteinases and their inhibitor TIMP. In: GalauertL (ed) The Control of Tissue Damage. Elsevier, NY, 1988, pp 223–241
WerbZ, MainardiCL, VaterCA, HibbsMS, HartyKA: Endogenous activation of latent collagenase by rheumatoid synovial cells: Evidence for a role of plasminogen activator. N Eng J Med 296: 1017, 1977
SchulzRM, SilbermanS, PerskyB, BajkowskiAS, CarmichaelPF: Inhibition by human recombinant tissue inhibitor of metalloproteinase of human amnion invasion and lung colonization by murine B16-FID melanoma cells. Cancer Res 48: 5539–5545, 1988
CawstonTE, NobelDN, MurphyG, SmithAJ, WoodleyC, HazlemanB: Rapid pufification of tissue inhibition of metalloproteinase from human plasma and identification as a serum G protein. Biochem J 239: 677–682, 1986
JanickeF, SchmittM, UlmK, GossnerW, GraeffH: The urokinase type plasminogen activator (uPA) antigen is related to early relapse in breast cancer. Lancet (ii): 1049, 1989
DuffyMJ, O'GradyP, DevaneyD, SiorainLO, FenellyJJ, LijnenHR: Tissue plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48: 1348–1349, 1988
DuffyMJ, O'GradyP, DevaneyD, O'SiorainL, FennellyJJ, LijnenHJ: Urokinase plasminogen activator: A marker for aggressive breast carcinomas: Preliminary report. Cancer 52: 531–533, 1988
JanickeF, SchmittM, GraeffH: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem Thromb Hemost 17: 303–313, 1991
DeRuinPA, GriffioenG, VerspagetHW, VerheijenJH, LamersCBHW: Plasminogen activators and tumor development in the human colin: Activity levels in normal mucosa, adenomatous tissues, polyps and adenocarcinomas. Cancer Res 47: L4654–4657, 1987
SappinoAP, HuarteJ, BelinD, VassalliJD: Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol 109: 2471–2479, 1989
FeinbergRF, KaoLC, HaimowitzJE, QueenanJTJr, WunTC, StrassJFIII, KlimanHJ: Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker for invading trophoblasts. Lab Invest 61: 20–26, 1989
MenoudPA, DebrotS, SchowingJ: Mouse neural crest cells secrete both urokinase type and tissue type plasminogen activatorsin vitro. Development 106: 685–690, 1989
EricksonCA, IsseroffRR: Plasminogen activator activity is associated with neural crest cell motility in tissue culture. J Exp Zool 251: 123–133, 1989
ValinskyJE, ReichE, LeDouarinN: Plasminogen activator in the bursa of Fabricius: Correlations with morphogenetic remodeling and cell migrations. Cell 25: 471–476, 1981
GudewiczPW, GilboaN: Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun 147: 1176–1181, 1987
KrawczykWK: A pattern of epidermal cell migration during wound healing. J Cell Biol 49: 247–263, 1971
AstrupT: Blood coagulation and fibrinolysis in tissue culture and tissue repair. Biochem Pharmacol 17 (Suppl): 241–257, 1968
ViziamCB, MatolstyAG, MesconH: Epithelialization of small wounds. J Invest Dermatol 43: 499–507, 1964
QuaxPHA, RrisalE, PedersenN, BonavaudS, VerheijenJH, BlasiF, Barlovatz-Meimon: Cell surface plasminogen activation is required for differentiation of human adult myogenic cellsin vitro. Thromb Hemost 65 (Abstr): 665, 1991
ClowesAW, MonikaM, ClowesYPT, AuYPT, ReidyMA, BelinD: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator durmigration in injured rat carotid artery. Cir Res 67: 61–67, 1990
GrossTJ, SimonRH, SitrinRG: Expression of urokinasetype plasminogen activator by rat pulmonary alveolar epithelial cells. Am J Respir Cell Mol Biol 3: 449–456, 1990
MarshallBC, SageserDS, RaoNV, EdmilM, HoidalJR: Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem 265: 8198–8204, 1990
LayerGT, BernardKG, GaffneyPJ, Cederholm-WilliamsSA, MahmoudM, HoulbrookS, PattisonM: Tissue plasminogen activators in breast cancer. Thromb Res 45: 601–607, 1987
Mira-y-LopezR, OsborneMP, DePaloAJ, OssowskiL: Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas; correlation with clinical outcome of antiestrogen therapy. Intl J Cancer 47: 827–832, 1991
DuffyMJ, ReillyD, O'sullivanC, O'HigginsN, FennellyJJ, AndreasenP: Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827–6829, 1990
DuffyMJ, ReilleyD, O'SullivanC, O'HigginsN, FennellyJJ: Urokinase plasminogen activator and prognosis in breast cancer. Lancet (i): 108, 1990
Reilly D, Andreasen P, Duffy MJ: Urokinase type plasmiinogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA levels. J Biochem Soc Trans 19: 44S, 1991
ReillyD, ChristensenL, DuchM, NolanN, DuffyMJ, AndreasenPA: Type 1 plasminogen activator inhibitor in human breast carcinomas. Intl J Cancer 50: 208–214, 1992
KirchheimerJ, LollerA, BinderBR: Isolation and characterization of plasminogen activators from hypersplenic and malignant prostate tissue. Biochim Biophys Acta 797: 256–265, 1984
KollerA, KirchheimerJ, PflugerH, BinderBR: Tissue plasminogen activator activity in prostate cancer. Eur Urol 10: 389–394, 1984
KirchheimerJC, PflugerH, RitschalP, HeinertG, BinderBR: Plasminogen activator activity in bone metastasis as compared to primary tumors. Invasion Metastasis 5: 344–355, 1985
HienertG, KirchheimerJC, PflugerH, BinderBR: Urokinase type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 140: 1466–1469, 1988
GaylisFD, KeerHN, WilsonMJ, KwaanHC, SinhaAA, KozlowskiJM: Plasminogen activator in human prostate cancer cell lines and tumors. Correlation with aggressive phenotype. J Urol 142: 193–198, 1989
KeerHN, GayulisFD, KozlowskiJM, KwaanHC, BauerKD, AkouchiA, SinhaAA, WilsonMJ: Heterogeneity in cellular level of expression of plasminogen activators in human prostate cancer cell lines. Invasive cells contain and secrete more uPA. The Prostate 18: 201–204, 1991
MarkusG, CamioloSM, KohgaS, MadjeaJM, MittelmanA: Plasminogen activator secretion of human tumors in short-term organ cultures, including a comparison of primary and metastatic colon tumors. Cancer Res 43: 5517–5525, 1983
KohgaS, HarverySR, WeaverRM, MarkusG: Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 45: 1787–1796, 1985
BoydD, FlorentG, KimP, BrattainM: Determinations of the levels of urokinase and its receptors in human colon carcinoma cell lines. Cancer Res 48: 3112–3116, 1988
deBruinPAF, GriffioenG, VerspagetHW, VerheijenJH, DooijewaardG, van denInghHF, LamersCBHW: Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 48: 4520–4524, 1988
BoydD, ZioberB, ChakrabartyS, BrattainM: Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res 49: 816–820, 1989
SchlechteW, MuranoG, BoydD: Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 49: 6064–6069, 1989
PykeC, KristensenP, RalfkiaerE, Grondahl-HansenJ, EriksenJ, BlasiF, DanoK: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059–1067, 1991
HollasW, BoydD: Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptors. Sem Thromb Hemost 17: 225–230, 1991
MarkusG, TakitaH, CamioloSM, CorasantiJG, EversJL, HobikaCH: Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 40: 841–848, 1980
TakahashiK, GojoboriT, TanifujiM: Two-color cytofluorometry and cellular properties of the urokinase receptor associated with a human metastatic carcinomatous cell line. Exp Cell Biol 192: 405–413, 1991
SeiffertD, MimuroJ, SchleefRR, LoskutoffDJ: Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev 32: 287–292, 1990
KirchheimerJC, WojtaJ, ChristG, BinderB: Proliferation of a human epidermal tumor cell line stimulated by urokinase. Proc Natl Acad Sci USA FASEB 1: 125–128, 1987
KirchheimerJC, WojtaJ, ChristG, BinderBR: Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 86: 5424–5428, 1989
GoltzmanD, BolivarI, MorozLA, RabbaniSA: Urokinase and the mechanism of osteoblastic metastases by prostate cancer. Fibrinolysis 1: 63–69, 1992
KirchheimerJC, WojtaJ, ChristG, HienertG, BinderBR: Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. Carcinogenesis 9: 2121–2123, 1988
KirchheimerJC, ChristG, BinderBR: Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 181: 103–107, 1987
WeissL: Cancer cell traffic from the lung to the liver: An example of metastatic inefficiency Int J Cancer 25: 385–392, 1980
MelzerMS: Macrophage activation for tumor cytoxicity characterization of primary and trigger signals during lymphokine activation. J Immunol 127: 179–183, 1981
HannaN: Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of NK cell-mediated cytotoxicity. Int J Cancer 26: 675–680, 1980
RosenbertSA, SpiessP, LafrenierR: A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 223: 1318–1321, 1986
RosensteinM, YoonI, KaufmanY, RosenbergSA: Lymphokine activated killer cells: Lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 44: 1946–1953, 1984
FidlerIJ, GerstenDN, HartIR: Pathogenesis of cancer metastasis. Adv Cancer Res 28: 149–260, 1978
SchirmacherV: Cancer metastasis: Experimental approaches, theoretical concepts and impacts for treatment strategy. Adv Cancer Res 43: 69–71, 1985
NicolsonGL: Cancer metastasis: Organ colonization and the surface properties of malignant cells. Biochim Biophys Acta 695: 113–176, 1982
GorelikE: Protective effect of fibrin on tumor metastasis. Fibrinolysis 1: 35–38, 1992
TuszynskiGP, GasicTB, RothmanVL, KnudsenKA, GlasicGI: Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47: 4130–4133, 1987
FukaoH, TanakaN, UeshimaS, OkadaK, YasutomiM, MatsuoO: Plasminogen activator inhibitor in stomach and colorectal carcinomas. Sem Thromb Hemost 17: 276–279, 1991
SappinoAP, BelinD, HuarteJ, Hirschel-ScholzS, SauratJH, VassalliJD: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073–1079, 1991
HearingVJ, LwaLW, CortiA, AppellaE, BlasiF: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270–1281, 1981
MeissauerA, KramerMD, HofmannM, ErkellLJ, JacobE, SchirrmacherV, BrunnerG: Urokinase type and tissue type plasminogen activators are essential forin vitro invasion of human melanoma cells. Exp Cell Res 192: 453–459, 1991
SaitoK, NagashimaM, IwataM, HamadaH, SumiyoshiK, TakadaY, TakadaA: The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 58: 355–366, 1990
AndreasenPA, NielsenLS, KristensenP, Grondahl-HansenJ, SilverL, DanoK: Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator but not its proenzyme. J Biol Chem 261: 7644–7651, 1986
RehemtullaA, MurphyP, DobsonM, HartDA: Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma U138. Cell Biol 66: 1270–1277, 1988
WilsonEJ, JacobsP, DowdleEB: The effects of dexamethasone and tetradecanoylphorbol acetate on plasminogen activator release by human acute myeloid leukemia cells. Blood 61: 561–567, 1983
WilsonEL, JacobsP, DowdleEB: The secretion of plasminogen activators by human myeloid leukemic cellsin vitro. Blood 61: 568–574, 1983
WilsonEL, JacobsP, OliverL: Plasminogen activator as a prognostic factor in haematological malignancies. In: NethR (ed) Haematology and Blood Transfusion. Springer-Verlag, Berlin, 1985, pp 197–199
StephensRW, AlitaloR, TapiovaaraH, VaheriA: Production of an active urokinase by leukemia cell lines: A novel distinction from cell lines of solid tumors. Leuk Res 12: 419–422, 1988
AlvingBM, KrishnamurtiC, LiuYP, LucasDL, WrightDG: Stimulated production of urokinase by plasminogen activator inhibitor 2 by the human promyelocytic leukemia cell line HL-60. Thromb Res 51: 175–185, 1988
OliverLO, KeetonM, WilsonEL: Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562). Blood 74: 1321–1327, 1989
TapiovaaraH, VaheriA, AlitaloR, SimPS, WoodrowG, StephensRW: Enhanced activation of prourokinase by human RC2A leukemia cells. Sem Thromb Hemost 17: 251–261, 1991
WilsonEL, JacobsP, FrancisGE, OliverL, BurgerP, DowdleEB: Secretion of plasminogen activators by normal bone marrow cells. Leukaemic myeloid cells. Fibrinolysis 6 (Suppl 1): 77–79, 1992
JanickeF, SchmittM, HafterR, HollreiderA, BabicR, UlmK, GossnerW, GraefJ: Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69–78, 1990
KwaanHC, KeerHN, RadosevichJA, CajotJF, ErnstR: Components of the plasminogen-plasmin system in human tumor cell lines. Sem Thromb Hemost 17: 175–182, 1991
HooseinNM, BoydD, HollasWJ, MazarA, HenkinJ, ChungLWK: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Com 3: 255–264, 1991
WilsonEL, FrancisGE: Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human haemopoietic cells. J Exp Med 165: 1609–1623, 1987
Brunner G, Gabrilove J, Rifkin DB, Wilson EL: Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphaatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 114 (in press)
HazudaDJ, StrickerJ, SimonP, YoungPR: Structure-function mapping of interleukin 1 precursors. J Biol Chem 266: 7081–7086, 1991
BennettB, BoothA, CrollA, DawsonAA: The bleeding disorder in acute promyelocytic leukemia: Fibrinolysis due to uPA rather than defibrination. Br J Haematol 71: 511–517, 1989
SakataY, MurakamiT, NoroA, MoriK, MatsudaM: The specific activity of plasminogen activator inhibitor 1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 77: 1949–1957, 1991
KellenJA, MirakianA, KolinA: Antimetastatic effect of amiloride in an animal tumor model. Anticancer Res 8: 1373–1376, 1988
OssowskiL, ReichE: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611–619, 1983
AxelrodJA, ReichR, MiskinR: Expression of human recombinant metastasis of H-ras-transformed HIH3T3 cells. Mol Cell Biol 9: 2133–2141, 1989
PlowEF, FelezJ, MilesLA: Cellular regulation of fibrindysis. Thromb Haemostas 66: 32–36, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kwaan, H.C. The plasminogen-plasmin system in malignancy. Cancer Metast Rev 11, 291–311 (1992). https://doi.org/10.1007/BF01307184
Issue Date:
DOI: https://doi.org/10.1007/BF01307184